desk
Share
News Topical, Digital Desk : Anthem Biosciences shares will be listed on the stock market on July 21, 2025. The company's IPO was open from July 14 to 16 and received tremendous interest from investors, receiving 63.86 times subscription. Market experts believe that Anthem Biosciences shares may be listed with a premium of up to 25% compared to the price band of Rs 540-570.
The company's strong fundamentals are the reason for this. However, the analyst has also warned that the company's performance in the long term will depend on margin stability, innovation and increasing customer reach globally.
First of all, know the details of this IPO ...
This Bangalore-based company raised Rs 1,016 crore from 60 anchor investors before the IPO. This IPO of Rs 3,395 crore was completely an offer-for-sale (OFS), in which 5.96 crore equity shares were sold. This means that the company will not get any funds, and all the money will go to the selling shareholders.
What is the functioning of this company?
Anthem Biosciences is a technology-based contract research, development and manufacturing organization (CRDMO) that provides services in the discovery, development and manufacturing of drugs. It works for both small molecules and biologics. The company is one of the few companies in the CRO and CRDMO sector in the pharmaceutical and biotechnology industry. It also manufactures specialty fermentation-based active pharmaceutical ingredients (APIs) such as probiotics, enzymes, peptides, nutritional active ingredients, vitamin analogs and biosimilars.
What is the opinion of experts? Narendra Solanki of Anand Rathi said, "The company's PE i.e. valuation based on FY25 earnings is 70.6 times. The market capitalization after the IPO is Rs 31,867 crore. Considering the strong growth, best margins in the industry and stable profits, this IPO is at a reasonable price. Investors who have been allotted shares should hold for the long term." Mahesh M. Ojha, AVP (Research and Business Development), Hensex Securities, said, "Strong demand from institutional investors could lead to a listing at Rs 700 or more, which would be at a 20-25% premium. In the short term, investors can book some profits on a higher listing. Long-term investors should keep an eye on margin trends, product innovation and growth in the number of customers. Those who could not participate in the IPO should wait for the stock to stabilize after listing." Harshal Dasani, Business Head, INVasset PMS, said, "If the listing meets grey market expectations and the company maintains earnings momentum in Q2, Anthem Biosciences could become a major player in India's biotech growth story."
What is Anthem Biosciences' GMP? As of July 17, 2025, Anthem Biosciences' GMP was Rs 138-156, indicating a 24-27% premium to the upper price band of Rs 570.
--Advertisement--
